Latest news: Vaccines authorized or under evaluation by EMA

Plenty of news regarding COVID-19 vaccines this week.

Plenty of news regarding COVID-19 vaccines this week.
March 4, 2021

Plenty of news regarding COVID-19 vaccines this week: on the one hand, today EMA announced that the Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of Sputnik V (Gam-COVID-VAC) COVID-19 Vaccine. On the other hand, EMA also notified that the CHMP will hold an extraordinary meeting on the 11th of March in order to conclude the evaluation of the COVID-19 vaccine developed by Janssen-Cilag International N.V. If there is a positive outcome to this meeting, the evaluation process (which started with a rolling review on December 2020 and was followed by the conditional marketing authorisation evaluation on mid-February 2021) would be completed. If this vaccine is authorized, a total of 4 vaccines will be available on the European market, with three more on the way, already under EMA’s evaluation.

Asphalion is actively aiding in the development of new medicines to treat or prevent COVID-19. With each announcement of the authorization of new treatments and the hope they bring with them, we are sure that this development projects are worth each ounce of the invested effort.

For further information you can contact us at:

Search News & Events

  • Filter by category


Related news and events

New! Clinical Data Publication (Policy 0070) re-launch

The scope of the policy relates to clinical data, composed of clinical reports and individual patient data (IPD), submitted under the centralised marketing authorisation procedure after the effective date (see chapter 4.3. for further information), either using the common technical document (CTD) format or another format

NEW! | The 3rd eAF-PMS Newsletter has been published on the EMA website!

This 3rd edition of the eAF-PMS
Newsletter highlights the latest news,
upcoming events and activities planned
for the next months. An updated
timeline of the web-based Human
Variations electronic application
form (eAF) accessible from the
Product Lifecycle Management
(PLM) Portal is now available to all
interested stakeholders. The timeline
highlights important milestones to be
achieved in the upcoming months with
regards to the release of new
functionalities, User Acceptance Testing
(UAT) and start of the transition period.
A version of the timeline highlighting
impacts on the eAF users in the
different periods is also available for
If you are interested in the progress of


During these two interactive days, leaders and world experts in biosimilar medicines will gather and debate the evolving biosimilar medicines landscape and new trends. Discussion will focus on the actions, changes, evolutions and re-thinking needed to achieve the depth, breadth and speed of the use of biosimilar medicines as a lever to realise the improvements in both health and access.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting